SOURCE: Avisio, Inc.

December 16, 2009 10:15 ET

Diagnostic Nano Applications Corporation Plans to Begin Testing Its Instant Detect Technology on H1N1 Virus

RIVERSIDE, CA--(Marketwire - December 16, 2009) - Diagnostic Nano Technology Corporation (DNA), a subsidiary of Avisio, Inc. (PINKSHEETS: AVIC), announced today that with the early laboratory success of its Instant Detect Technology in the detection of certain viruses that cause Dengue Fever, it plans to begin testing the technology on the detection of the H1N1 virus.

"Ongoing testing of this type is a necessary component in the process of selecting DNA's initial human application development projects," said Amro Albanna, CEO of DNA and Avisio, Inc. "We are cautiously optimistic about the market opportunity that exists for DNA's Instant Detect product, especially with regard to potential human applications. We realize that we are early in the process and still have a number of milestones to reach, including but not limited to further proof of concept, the ability to produce product at scale, third-party validation and regulatory approvals, before we can begin to market a product," continued Albanna.

About Avisio, Inc.

Avisio, Inc. is a publicly-traded technology commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses. Avisio plans to create a new majority-owned private subsidiary around each asset and to support each business with experienced management teams, best-of-breed commercialization processes and resources, and access to global capital sources. For more information, please visit

Safe Harbor Statement

The statements contained in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including, but not limited to, the company's ability to develop, test, undergo third-party validation and commercialize the H1N1 test chip, are not guarantees of future performance and involve certain assumptions and certain risks and uncertainties that are difficult to predict. Actual outcomes and results may differ materially from what is expressed in, or implied by, such forward-looking statements. Among the important factors that could cause actual results to differ materially from those expressed in or implied by, the forward-looking statements are the company's ability to finance the research and development of the H1N1 test chip and test, validate and commercialize the H1N1 test chip. Avisio's actual results could differ materially from those anticipated in the forward-looking statements and you should not place any undue reliance on such forward-looking statements. The forward-looking statements in this news release are made as of the date hereof, and Avisio does not assume any obligation to update, amend or clarify them to reflect events, new information or circumstances occurring after the date hereof.

Contact Information